Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy. - Wikidata - wikimedia - TriplyDB

Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy.

Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy.

http://www.wikidata.org/entity/Q34957256

about

Inhibitors of the Hepatitis C Virus Polymerase; Mode of Action and Resistance What Are the Prospects for Controlling Hepatitis C?Hepatitis C: recent successes and continuing challenges in the development of improved treatment modalities High Affinity Peptide Inhibitors of the Hepatitis C Virus NS3-4A Protease Refractory to Common Resistant Mutants State of the Art, Unresolved Issues, and Future Research Directions in the Fight against Hepatitis C Virus: Perspectives for Screening, Diagnostics of Resistances, and Immunization Influence of host resistance on viral adaptation: hepatitis C virus as a case study Deep sequencing analysis of HCV NS3 resistance-associated variants and mutation linkage in liver transplant recipients HCV genotype-3a T cell immunity: specificity, function and impact of therapy Naturally occurring drug resistance associated variants to hepatitis C virus direct-acting antiviral agents in treatment-naive HCV genotype 1b-infected patients in China.Identification of HCV Resistant Variants against Direct Acting Antivirals in Plasma and Liver of Treatment Naïve Patients Effects of HIV type-1 immune selection on susceptability to integrase inhibitor resistance.Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C.Linking pig-tailed macaque major histocompatibility complex class I haplotypes and cytotoxic T lymphocyte escape mutations in simian immunodeficiency virus infection Nationwide experience of treatment with protease inhibitors in chronic hepatitis C patients in Denmark: identification of viral resistance mutations.Ultradeep pyrosequencing of NS3 to predict response to triple therapy with protease inhibitors in previously treated chronic hepatitis C patients.Naturally occurring dominant drug resistance mutations occur infrequently in the setting of recently acquired hepatitis C.Inhibitors of the Hepatitis C Virus RNA-Dependent RNA Polymerase NS5B.Compensatory mutations restore the replication defects caused by cytotoxic T lymphocyte escape mutations in hepatitis C virus polymerase.Naturally Occurring Resistance-Associated Variants of Hepatitis C Virus Protease Inhibitors in Poor Responders to Pegylated Interferon-Ribavirin.Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected Patients.Characterization of resistance to the nonnucleoside NS5B inhibitor filibuvir in hepatitis C virus-infected patients.Analysis of hepatitis C virus intrahost diversity across the coding region by ultradeep pyrosequencing Update on hepatitis C virus-specific immunity Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir Phylogenetic analysis of isolated HCV strains from tunisian hemodialysis patients.Dynamics of resistance mutations to NS3 protease inhibitors in a cohort of Brazilian patients chronically infected with hepatitis C virus (genotype 1) treated with pegylated interferon and ribavirin: a prospective longitudinal study Evaluating the Role of Cellular Immune Responses in the Emergence of HCV NS3 Resistance Mutations During Protease Inhibitor Therapy HLA-B*27 subtype specificity determines targeting and viral evolution of a hepatitis C virus-specific CD8+ T cell epitope.Dynamic evolution of hepatitis C virus resistance-associated substitutions in the absence of antiviral treatment.Pretreatment resistance to hepatitis C virus protease inhibitors boceprevir/telaprevir in hepatitis C virus subgenotype 1a-infected patients from Manitoba Management of HIV and hepatitis virus coinfection.Adaptive immunity to the hepatitis C virus.Treatment failure with new hepatitis C drugs.Hepatitis C virus resistance to new specifically-targeted antiviral therapy: A public health perspective.NS3 protease polymorphisms and genetic barrier to drug resistance of distinct hepatitis C virus genotypes from worldwide treatment-naïve subjects.Hepatitis C virus genetic variability and the presence of NS5B resistance-associated mutations as natural polymorphisms in selected genotypes could affect the response to NS5B inhibitors.Analysis of resistance-associated substitutions in acute hepatitis C virus infection by deep sequencing across six genotypes and three continents.Natural occurrence of NS5B inhibitor resistance-associated variants in Brazilian patients infected with HCV or HCV and HIV.A new subtype of hepatitis C virus genotype 3: analysis of available evidence Tracking the evolution of multiple in vitro hepatitis C virus replicon variants under protease inhibitor selection pressure by 454 deep sequencing.

P2860

Q26783056-90C21AE0-630A-48BA-8E98-97E53154DC69 Q27488436-45ED8AB0-0B06-458F-9249-BDBF2BCC4A8E Q27490426-190B1C45-11EA-4B41-A599-593E598ADCC3 Q27672908-6FEEA0A1-C3BF-4CB5-AF9D-49B091285E8D Q28079102-3DE1597A-22BF-428E-916A-D9508E7259CE Q28087595-C7D605B7-2A27-4FC4-AD29-771040387A51 Q28534965-915B680B-46EC-48C5-BF39-DD0138E85456 Q28687729-55CA7BE6-803F-40FB-B96A-0F48A3A40802 Q33672648-DA84E26D-E679-4365-8285-117DB9BE7325 Q33875539-AB07451E-CC50-45EF-BE22-E484127DE4F8 Q34136227-70775E24-3690-4083-A051-C41756B51970 Q34489239-AAB50B53-BBF5-4A28-BF07-B7A70BFA8791 Q34595036-DD917D34-0BA7-44DF-A76E-CEB1D7CC8C64 Q34599453-C00D2FAD-09BD-44D5-BB04-A1CB71A54DF6 Q34983102-5B8C1A83-4B87-4538-8319-BE65F466E9DB Q35061753-AF2D3652-1C33-4E88-88BF-123F60D51C18 Q35260330-5D7D0468-3C6B-43B3-AF67-2AF4962DE87D Q35531173-4A2B4ADD-FF0A-407D-953C-3E27AE5D5279 Q35757761-3AA7936D-F0DB-45C9-BBD7-5E5C4F0957F4 Q35759025-C26A3FC8-089C-4EFF-AC1C-CF89DD96AC9E Q35806182-C456379F-7EFE-4D86-BDCE-92E44F0BEBD5 Q35826862-B11FE501-0004-4CD0-9017-22E568C63E88 Q35839496-1824BE54-CFC8-47C3-B7EA-6EB7C4D699B8 Q36086454-73531482-376B-49A1-B995-0A46C636D90E Q36626705-3409CD56-7D1D-4806-977E-77BA9ECEBCFD Q36689877-1156B018-6438-4A17-9F51-475990654BF5 Q36881967-6382EF21-9447-4FEC-9A4B-BA0ED5D30E8A Q37402195-6D6E3086-9D36-48C4-B1C1-7BE837315202 Q37615174-A771810F-9C7A-47EA-9D37-24CB06E56D63 Q37640610-2137CFEC-06BF-4D3D-9344-E25C7E13E7FB Q37772508-0E1ADF00-B185-45C9-B79C-35F424BA3076 Q37805839-F6FC2B14-E6DC-4875-8B93-A6C1EAE05FF1 Q37975543-BD9230F8-EE8C-401B-A622-A0F76BAF2801 Q38156875-5DEEE59B-91C0-4304-ADD3-0FA1EFB90D68 Q38699377-D39DA561-8555-4BA1-82EC-062ABBED3EE0 Q38849307-04675D84-38EC-43FE-A589-0D9501498E24 Q38992902-95AF2AAF-B4AF-4E76-A598-2C8B12A90DF3 Q39307349-BCBF0E14-0D77-429A-AD06-785935382611 Q39338665-B61006CE-095C-4110-A0F3-16F6C13A50C3 Q39663398-6DFCB06E-0A10-4498-976D-30178D629FBB

P2860

Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy.

http://www.wikidata.org/entity/Q34957256

description

2009 nî lūn-bûn

@nan

2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Hepatitis C virus drug resista ...... ance to new antiviral therapy.

@ast

Hepatitis C virus drug resista ...... ance to new antiviral therapy.

@en

Hepatitis C virus drug resista ...... ance to new antiviral therapy.

@nl

type

label

Hepatitis C virus drug resista ...... ance to new antiviral therapy.

@ast

Hepatitis C virus drug resista ...... ance to new antiviral therapy.

@en

Hepatitis C virus drug resista ...... ance to new antiviral therapy.

@nl

prefLabel

Hepatitis C virus drug resista ...... ance to new antiviral therapy.

@ast

Hepatitis C virus drug resista ...... ance to new antiviral therapy.

@en

Hepatitis C virus drug resista ...... ance to new antiviral therapy.

@nl

P1433

Q34957256-375618A8-BA25-4C6E-82E2-861CC3B0562A

P1476

Q34957256-98ABE97D-5638-4DB8-9693-52CC3AEFDD2A

P2093

Q34957256-0B4AE84C-32D9-4B55-86EC-4C43E08F6901

Q34957256-2EDD2064-7FBE-483E-8C51-E65CC63C69B8

Q34957256-36AC5E8B-3445-4761-8D9E-96871792B7E9

Q34957256-40332136-0B92-4E5B-828E-730748149115

Q34957256-4DD039A7-860E-494D-A3FD-640670840D63

Q34957256-59BF7A09-0CE0-4EBD-8AC2-998908697538

Q34957256-5D2F5BA7-47B6-438D-BF60-FB755D9BE631

Q34957256-802BE050-852C-4774-8661-BFF22C176E3F

Q34957256-9496D2AF-339B-4019-978E-65B718BF2E5E

Q34957256-96722E56-EA03-43D3-9936-A32899937A01

P2860

Q34957256-0D8D234D-8FD2-45DB-99B5-7A48B1E12855

Q34957256-158DEC96-B636-4BEE-9383-FB2212B7F27E

Q34957256-15E52001-DEBB-4A82-A844-D3125AC66276

Q34957256-1FC00855-703C-4AA5-9EBE-F656B2D03865

Q34957256-27C0710B-E6E1-40BE-ADDD-D7578E206CFE

Q34957256-27CA5AF4-FAFC-407C-B1AC-892F912495D4

Q34957256-29E677B8-2F9B-4989-9106-0A4792A7C80E

Q34957256-3BA642F8-8E05-4E9C-B858-A97EAA7F6538

Q34957256-4171E16F-F1C9-4174-8C0D-38F07659A7CB

Q34957256-41AF2C47-6090-4D9D-A470-556286C8E83B

P304

Q34957256-9194C479-2648-4162-883D-E2C8308686C6

P31

Q34957256-0ADF0277-8256-4E45-9269-785BD66C7036

P356

Q34957256-A9FC7F7D-7133-4CAE-A165-09E2E7B25CE6

P407

Q34957256-B2AED598-218C-426A-A798-4E15F7BE6B3E

P433

Q34957256-B8A4A351-9746-4B40-9762-11D2482F0C41

P478

Q34957256-17617199-D263-4230-97F7-32B2E30747A6

P50

Q34957256-3024CC2C-6659-4AD2-A8BE-83892743EED4

Q34957256-BB59C2DE-33CD-40BA-8DB8-AD6D20262A13

Q34957256-DB9F7D8D-E0B9-4521-8A0D-834A8EDE5668

Q34957256-FA7EC137-C138-4856-9C39-C634F7AA6415

P577

Q34957256-7B4EE480-64BF-45C6-B7A7-9E58EE73FA2D

P5875

Q34957256-3E487FF7-407D-4255-93EA-F00B0EE32B6A

P698

Q34957256-50AC932F-617B-4F59-9950-7D35A441C7AE

P356

P1433

P1476

Hepatitis C virus drug resista ...... ance to new antiviral therapy.

@en

P2093

Andri Rauch

http://www.w3.org/2001/XMLSchema#string

David Nolan

http://www.w3.org/2001/XMLSchema#string

Eleanor Barnes

http://www.w3.org/2001/XMLSchema#string

Elizabeth Freitas

http://www.w3.org/2001/XMLSchema#string

Gary P Jeffrey

http://www.w3.org/2001/XMLSchema#string

Geoff McCaughan

http://www.w3.org/2001/XMLSchema#string

Ian James

http://www.w3.org/2001/XMLSchema#string

Isla Humphreys

http://www.w3.org/2001/XMLSchema#string

Katja Pfafferott

http://www.w3.org/2001/XMLSchema#string

Lindsay Mollison

http://www.w3.org/2001/XMLSchema#string

P2860

Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro.

Selection and Characterization of Replicon Variants Dually Resistant to Thumb- and Palm-Binding Nonnucleoside Polymerase Inhibitors of the Hepatitis C Virus

Evidence of Viral Adaptation to HLA Class I-Restricted Immune Pressure in Chronic Hepatitis C Virus Infection

Evolution of Resistant M414T Mutants among Hepatitis C Virus Replicon Cells Treated with Polymerase Inhibitor A-782759

Activity of a Potent Hepatitis C Virus Polymerase Inhibitor in the Chimpanzee Model

CD8 Epitope Escape and Reversion in Acute HCV Infection

Phenotypic Characterization of Resistant Val36 Variants of Hepatitis C Virus NS3-4A Serine Protease

Relative Replication Capacity and Selective Advantage Profiles of Protease Inhibitor-Resistant Hepatitis C Virus (HCV) NS3 Protease Mutants in the HCV Genotype 1b Replicon System

The Hepatitis C Virus Replicon Presents a Higher Barrier to Resistance to Nucleoside Analogs than to Nonnucleoside Polymerase or Protease Inhibitors

Resistance Profile of a Hepatitis C Virus RNA-Dependent RNA Polymerase Benzothiadiazine Inhibitor

P304

1069-1082

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEP.22773

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

49

http://www.w3.org/2001/XMLSchema#string

P50

Hansjakob Furrer

Huldrych F Günthard

Silvana Gaudieri

P577

2009-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24179356

http://www.w3.org/2001/XMLSchema#string

P698

19263475

http://www.w3.org/2001/XMLSchema#string